Sirtex and Magle Chemoswed have entered into a development and commercial agreement focused on generating a novel imaging agent for use in the Interventional Oncology field. The development program commences in Q3, 2020. Magle Chemoswed maintains rights to its technology platform and to exclusively manufacture the product for supply to Sirtex. Sirtex shall have the exclusive license and commercialisation rights in the defined field of use.
 
“This is an incredibly exciting collaboration with a recognized global leader in the industry. With Sirtex’s expertise and experience, we will be able to move the project from development to regulatory approvals and commercialisation quickly, and we look forward to working together closely for optimal success,” says Justin Pierce, Magle Chemoswed’s CEO.
 
“We’re honored to partner with Magle Chemoswed and combine our expertise and resources to advance patient care globally,” said Kevin R. Smith, Chief Executive Officer of Sirtex. “This collaborative effort expands our portfolio of technologies and demonstrates a shared commitment to innovation.”
 
Sirtex Medical is a global healthcare business with offices in the US, Australia, Germany and Singapore, working to improve outcomes in people with cancer. Sirtex's current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres.